Bozkurt, B. et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J. Card. Fail. 29, 1412–1451 (2023).
Fedeli, U. et al. Mortality from chronic liver disease: recent trends and impact of the COVID-19 pandemic. World J. Gastroenterol. 29, 4166–4173 (2023).
World Health Organization. Chronic obstructive pulmonary disease (COPD); https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (2024).
Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. 12, 7–11 (2022).
Rana, A. et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 150, 252–259 (2015).
Statista. Estimated number of organ transplantations worldwide in 2023; https://www.statista.com/statistics/398645/global-estimation-of-organ-transplantations/ (2024).
Eurotransplant. Eurotransplant Annual Report 2023; https://www.eurotransplant.org/wp-content/uploads/2024/06/ETP_AR2023_LowRes.pdf (2024).
Chesnaye, N. C., Ortiz, A., Zoccali, C., Stel, V. S. & Jager, K. J. The impact of population ageing on the burden of chronic kidney disease. Nat. Rev. Nephrol. 20, 569–585 (2024).
Guha, A. et al. Implication of ventricular assist devices in extracorporeal membranous oxygenation patients listed for heart transplantation. J. Clin. Med. 8, 572 (2019).
Pockros, B. M., Finch, D. J. & Weiner, D. E. Dialysis and total health care costs in the United States and worldwide: the financial impact of a single-payer dominant system in the US. J. Am. Soc. Nephrol. 32, 2137–2139 (2021).
Chadban, S. et al. Projecting the economic burden of chronic kidney disease at the patient level (inside CKD): a microsimulation modelling study. EClinicalMedicine 72, 102615 (2024).
Wang, Y. et al. Pig-to-human kidney xenotransplants using genetically modified minipigs. Cell Rep. Med. 5, 101744 (2024).
Mehta, M., Hosgood, S. & Nicholson, M. L. Protocol for a single-centre randomised pilot study to assess the safety and feasibility of adding a CytoSorb filter during kidney normothermic machine perfusion to remove inflammatory and immune mediators prior to kidney transplantation. BMJ Open 15, e093001 (2025).
Hosgood, S. A. et al. Normothermic machine perfusion versus static cold storage in donation after circulatory death kidney transplantation: a randomized controlled trial. Nat. Med. 29, 1511–1519 (2023).
Schlegel, A. et al. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. J. Hepatol. 78, 783–793 (2023).
Ardehali, A. et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet 385, 2577–2584 (2015).
Schroder, J. N. et al. Increasing utilization of extended criteria donor hearts for transplantation. JACC Heart Fail. 12, 438–447 (2024).
Loupy, A., Mengel, M. & Haas, M. Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics. Kidney Int. 101, 678–691 (2022).
Cozzi, E., Colpo, A. & De Silvestro, G. The mechanisms of rejection in solid organ transplantation. Transfus. Apher. Sci. 56, 498–505 (2017).
De Graav, G. N. et al. New developments and therapeutic drug monitoring options in costimulatory blockade in solid organ transplantation: a systematic critical review. Ther. Drug Monit. 47, 64–76 (2025).
Fodor Duric, L., Basic Jukic, N. & Vujicic, B. Comparison of autologous and allogeneic adipose-derived stem cells in kidney transplantation: immunological considerations and therapeutic efficacy. J. Clin. Med. 13, 5763 (2024).
Zhang, W. et al. Patch grafting, strategies for transplantation of organoids into solid organs such as liver. Biomaterials 277, 121067 (2021).
Mohiuddin, M. M. et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet 402, 397–410 (2023).
Anand, R. P. et al. Design and testing of a humanized porcine donor for xenotransplantation. Nature 622, 393–401 (2023).
Poirier, N. et al. Inducing CTLA-4–dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2, 17ra10 (2010).
Loupy, A. et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 366, l4923 (2019).
Zhang, X., Gavaldà, R. & Baixeries, J. Interpretable prediction of mortality in liver transplant recipients based on machine learning. Comput. Biol. Med. 151, 106188 (2022).
Bartosh, T. J. et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc. Natl Acad. Sci. USA 107, 13724–13729 (2010).
Sablik, M. et al. Microvascular inflammation of kidney allografts and clinical outcomes. N. Engl. J. Med. 392, 763–776 (2025).
Khush, K. K. et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult heart transplantation report — 2019; focus theme: donor and recipient size match. J. Heart Lung Transplant. 38, 1056–1066 (2019).
Halverson, L. P. & Hachem, R. R. Antibody-mediated rejection. Clin. Chest Med. 44, 95–103 (2023).
Van Der Mark, S. C., Hoek, R. A. S. & Hellemons, M. E. Developments in lung transplantation over the past decade. Eur. Respir. Rev. 29, 190132 (2020).
Choudhary, N. S. et al. Acute and chronic rejection after liver transplantation: what a clinician needs to know. J. Clin. Exp. Hepatol. 7, 358–366 (2017).
Manzia, T. M. et al. Immunosuppression in adult liver transplant recipients: a 2024 update from the italian liver transplant working group. Hepatol. Int. 18, 1416–1430 (2024).
Lucey, M. R., Furuya, K. N. & Foley, D. P. Liver transplantation. N. Engl. J. Med. 389, 1888–1900 (2023).
Fernando, J. J., Biswas, R. & Biswas, L. Non‐invasive molecular biomarkers for monitoring solid organ transplantation: a comprehensive overview. Int. J. Immunogenet. 51, 47–62 (2024).
Millán, O., Julian, J. & Brunet, M. miRNAs, dd-cf-DNA, and chemokines as potential noninvasive biomarkers for the assessment of clinical graft evolution and personalized immunosuppression requirement in solid organ transplantation. Ther. Drug Monit. 47, 77–97 (2025).
Madill-Thomsen, K. S. & Halloran, P. F. Precision diagnostics in transplanted organs using microarray-assessed gene expression: concepts and technical methods of the molecular microscope diagnostic system (MMDx). Clin. Sci. 138, 663–685 (2024).
Halloran, P. F. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351, 2715–2729 (2004).
Ufere, N. N., Satapathy, N., Philpotts, L., Lai, J. C. & Serper, M. Financial burden in adults with chronic liver disease: a scoping review. Liver Transpl. 28, 1920–1935 (2022).
Jha, V. et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv. Ther. 40, 4405–4420 (2023).
Al Moussawy, M., Lakkis, Z. S., Ansari, Z. A., Cherukuri, A. R. & Abou-Daya, K. I. The transformative potential of artificial intelligence in solid organ transplantation. Front. Transplant. 3, 1361491 (2024).
Kamath, P. S. & Kim, W. R. The model for end-stage liver disease (MELD). Hepatology 45, 797–805 (2007).
Bertsimas, D. et al. Development and validation of an optimized prediction of mortality for candidates awaiting liver transplantation. Am. J. Transplant. 19, 1109–1118 (2019).
Brüggenwirth, I. M. A. et al. The liver retransplantation risk score: a prognostic model for survival after adult liver retransplantation. Transpl. Int. 34, 1928–1937 (2021).
Truchot, A. et al. Extended validations of the iBox system in real life settings. In 22nd Congress of the European Society for Organ Transplantation Abstract FOS_06_1 (ESOT, 2025).
Klein, A. et al. Qualifying a novel clinical trial endpoint (iBOX) predictive of long-term kidney transplant outcomes. Am. J. Transplant. 23, 1496–1506 (2023).
Raynaud, M. et al. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. Lancet Digit. Health 3, e795–e805 (2021).
Loupy, A. et al. Identification and characterization of trajectories of cardiac allograft vasculopathy after heart transplantation: a population-based study. Circulation 141, 1954–1967 (2020).
Loftus, T. J. et al. Artificial intelligence-enabled decision support in nephrology. Nat. Rev. Nephrol. 18, 452–465 (2022).
Monlezun, D. J., Samura, A. T., Patel, R. S., Thannoun, T. E. & Balan, P. Racial and socioeconomic disparities in out-of-hospital cardiac arrest outcomes: artificial intelligence-augmented propensity score and geospatial cohort analysis of 3,952 patients. Cardiol. Res. Pract. 2021, 3180987 (2021).
Becker, J. U. et al. Artificial intelligence and machine learning in nephropathology. Kidney Int. 98, 65–75 (2020).
Peyster, E. et al. Computational pathology assessments of cardiac stromal remodeling: clinical correlates and prognostic implications in heart transplantation. JHLT Open 7, 100202 (2024).
Yoo, D. et al. An automated histological classification system for precision diagnostics of kidney allografts. Nat. Med. 29, 1211–1220 (2023).
Demir, Z. et al. Identification of liver transplant biopsy phenotypes associated with distinct liver biological markers and allograft survival. Am. J. Transplant. 24, 954–966 (2024).
Zielinski, D. et al. Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant (B-HOT) gene panel: a multicenter international study. Am. J. Transplant. https://doi.org/10.1016/j.ajt.2025.04.025 (2025).
Spooner, A. et al. Benchmarking ensemble machine learning algorithms for multi-class, multi-omics data integration in clinical outcome prediction. Brief. Bioinform. 26, bbaf116 (2025).
Khanal, B. et al. Investigating the robustness of vision transformers against label noise in medical image classification. Ann. Int. Conf. IEEE Eng. Med. Biol. Soc. 2024, 1–6 (2024).
Tasca, P. et al. Application of spatial-omics to the classification of kidney biopsy samples in transplantation. Nat. Rev. Nephrol. 20, 755–766 (2024).
Amancherla, K. et al. Dynamic responses to rejection in the transplanted human heart revealed through spatial transcriptomics. Preprint at bioRxiv https://doi.org/10.1101/2025.02.28.640852 (2025).
Kang, M. et al. Spatial transcriptomic signatures of early acute T cell–mediated rejection in kidney transplants. Transplant. Direct 10, e1705 (2024).
Martin-Martin, C. et al. Exploring kidney allograft rejection: a proof-of-concept study using spatial transcriptomics. Am. J. Transplant. 24, 1161–1171 (2024).
Mou, L. et al. Single-cell genomics and spatial transcriptomics in islet transplantation for diabetes treatment: advancing towards personalized therapies. Front. Immunol. 16, 1554876 (2025).
Chauveau, B., Couzi, L. & Merville, P. The microscope and beyond: current trends in the characterization of kidney allograft rejection from tissue samples. Transplantation 109, 440–453 (2025).
Cross, A. R., Gartner, L., Hester, J. & Issa, F. Opportunities for high-plex spatial transcriptomics in solid organ transplantation. Transplantation 107, 2464–2472 (2023).
Noel, T., Wang, Q. S., Greka, A. & Marshall, J. L. Principles of spatial transcriptomics analysis: a practical walk-through in kidney tissue. Front. Physiol. 12, 809346 (2022).
Pilch, N. A., Bowman, L. J. & Taber, D. J. Immunosuppression trends in solid organ transplantation: the future of individualization, monitoring, and management. Pharmacotherapy 41, 119–131 (2021).
Dunn, D. L. Problems related to immunosuppression. Infection and malignancy occurring after solid organ transplantation. Crit. Care Clin. 6, 955–977 (1990).
Kasiske, B. L. Payment for immunosuppression after organ transplantation. JAMA 283, 2445–2450 (2000).
Aubert, O. et al. Cell-free DNA for the detection of kidney allograft rejection. Nat. Med. 30, 2320–2327 (2024).
Van Rijn, A., Roos, R., Dekker, F., Rotmans, J. & Feltkamp, M. Torque teno virus load as marker of rejection and infection in solid organ transplantation – a systematic review and meta-analysis. Rev. Med. Virol. 33, e2393 (2023).
Thishya, K., Vattam, K. K., Naushad, S. M., Raju, S. B. & Kutala, V. K. Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation. PLoS ONE 13, e0191921 (2018).
Süsal, C. & Döhler, B. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: a collaborative transplant study report. Am. J. Transplant. 19, 2805–2813 (2019).
Wang, Z. et al. Locally controlled release of immunosuppressive promotes survival of transplanted adult spinal cord tissue. Regen. Biomater. 10, rbac097 (2023).
Chang, C. -C. et al. A peptide derived from interleukin-10 exhibits potential anticancer activity and can facilitate cell targeting of gold nanoparticles loaded with anticancer therapeutics. Commun. Chem. 6, 278 (2023).
Cassano, A., Chong, A. S. & Alegre, M. -L. Tregs in transplantation tolerance: role and therapeutic potential. Front. Transplant. 2, 1217065 (2023).
Bézie, S., Anegon, I. & Guillonneau, C. Advances on CD8+ Treg cells and their potential in transplantation. Transplantation 102, 1467–1478 (2018).
Sawitzki, B. et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet 395, 1627–1639 (2020).
Proics, E. et al. Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation. Gene Ther. 30, 309–322 (2023).
European Cooperation in Science and Technology (COST). BM1305 – action to focus and accelerate cell-based tolerance-inducing therapies (A FACTT); https://www.cost.eu/actions/BM1305/ (2018).
European Cooperation in Science and Technology. COST Action Mye-EUNITER establish a common yet robust protocol for the comparative analysis of myeloid cells (MDSC) in various diseases; https://www.cost.eu/breaking-boundaries-cost-action-mye-euniter/ (2020).
INsTRuCT Consortium. A network of European scientists from academic and industry focused on developing innovative myeloid regulatory cell (MRC)-based immunotherapies; https://instruct-h2020.eu/consortium (2020).
Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41–58 (2019).
Corsello, S. M. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235–248 (2020).
Zhang, Q. et al. Drug repurposing: ibrutinib exhibits immunosuppressive potential in organ transplantation. Int. J. Med. Sci. 15, 1118–1128 (2018).
Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 6, 14 (2020).
Laubenbacher, R. et al. Building digital twins of the human immune system: toward a roadmap. NPJ Digit. Med. 5, 64 (2022).
Montgomery, R. A. et al. Results of two cases of pig-to-human kidney xenotransplantation. N. Engl. J. Med. 386, 1889–1898 (2022).
Porrett, P. M. et al. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am. J. Transplant. 22, 1037–1053 (2022).
Locke, J. E., Kumar, V., Anderson, D. & Porrett, P. M. Normal graft function after pig-to-human kidney xenotransplant. JAMA Surg. 158, 1106–1108 (2023).
NYU Langone Health. wo-month study of pig kidney xenotransplantation gives new hope to the future of the organ supply; https://nyulangone.org/news/two-month-study-pig-kidney-xenotransplantation-gives-new-hope-future-organ-supply (2023).
Kawai, T. et al. Xenotransplantation of a porcine kidney for end-stage kidney disease. N. Engl. J. Med. 392, 1933–1940 (2025).
NYU Langone Health. First-ever combined heart pump and pig kidney transplant gives new hope to patient with terminal illness; https://nyulangone.org/news/first-ever-combined-heart-pump-gene-edited-pig-kidney-transplant-gives-new-hope-patient-terminal-illness (2024).
NYU Langone Health. Gene-edited pig kidney gives living donor new lease on life; https://nyulangone.org/news/gene-edited-pig-kidney-gives-living-donor-new-lease-life (2024).
Griffith, B. P. et al. Genetically modified porcine-to-human cardiac xenotransplantation. N. Engl. J. Med. 387, 35–44 (2022).
Tao, K. -S. et al. Gene-modified pig-to-human liver xenotransplantation. Nature 641, 1029–1036 (2025).
Mallapaty, S. First pig-to-human liver transplant recipient ‘doing very well’. Nature 630, 18–18 (2024).
US Food & Drug Administration. Xenotransplantation; https://www.fda.gov/vaccines-blood-biologics/xenotransplantation (2021).
Cooper, D. K. C. & Cozzi, E. Clinical pig heart xenotransplantation—where do we go from here? Transpl. Int. 37, 12592 (2024).
Griffith, B. P. et al. Transplantation of a genetically modified porcine heart into a live human. Nat. Med. 31, 589–598 (2025).
Moazami, N. et al. Pig-to-human heart xenotransplantation in two recently deceased human recipients. Nat. Med. 29, 1989–1997 (2023).
Kotz, D. In Memoriam: Lawrence Faucette. University of Maryland School of Medicine. https://www.medschool.umaryland.edu/news/2023/in-memoriam-lawrence-faucette.html (2023).
Eisenson, D. L., Hisadome, Y. & Yamada, K. Progress in xenotransplantation: immunologic barriers, advances in gene editing, and successful tolerance induction strategies in pig-to-primate transplantation. Front. Immunol. 13, 899657 (2022).
Cross-Najafi, A. A. et al. Current barriers to clinical liver xenotransplantation. Front. Immunol. 13, 827535 (2022).
Zhang, X. et al. A review of pig liver xenotransplantation: current problems and recent progress. Xenotransplantation 26, e12497 (2019).
Loupy, A. et al. Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study. Lancet 402, 1158–1169 (2023).
Samy, K. P., Butler, J. R., Li, P., Cooper, D. K. C. & Ekser, B. The role of costimulation blockade in solid organ and islet xenotransplantation. J. Immunol. Res. 2017, 1–11 (2017).
Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8, 315–317 (2006).
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
Hyun, I. The bioethics of stem cell research and therapy. J. Clin. Invest. 120, 71–75 (2010).
Yamanaka, S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10, 678–684 (2012).
Wnorowski, A., Yang, H. & Wu, J. C. Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. Adv. Drug Deliv. Rev. 140, 3–11 (2019).
Wang, S. et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell 187, 6152–6164 (2024).
Guilak, F. et al. Control of stem cell fate by physical interactions with the extracellular matrix. Cell Stem Cell 5, 17–26 (2009).
Zhao, Z. et al. Organoids. Nat. Rev. Methods Primers 2, 94 (2022).
McKee, C. & Chaudhry, G. R. Advances and challenges in stem cell culture. Colloids Surf. B Biointerfaces 159, 62–77 (2017).
Dzobo, K. et al. Advances in regenerative medicine and tissue engineering: innovation and transformation of medicine. Stem Cells Int. 2018, 2495848 (2018).
Shopova, D. et al. (Bio)printing in personalized medicine-opportunities and potential benefits. Bioengineering 10, 287 (2023).
Li, P. et al. The potential role of 3D-bioprinting in xenotransplantation. Curr. Opin. Organ Transplant. 24, 547–554 (2019).
Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. Nat. Biotechnol. 32, 773–785 (2014).
Vanaei, S., Parizi, M. S., Vanaei, S., Salemizadehparizi, F. & Vanaei, H. R. An overview on materials and techniques in 3D bioprinting toward biomedical application. Eng. Regen. 2, 1–18 (2021).
Ricci, G., Gibelli, F. & Sirignano, A. Three-dimensional bioprinting of human organs and tissues: bioethical and medico-legal implications examined through a scoping review. Bioengineering 10, 1052 (2023).
Pipis, N., James, B. D. & Allen, J. B. Multifunctional DNA-collagen biomaterials: developmental advances and biomedical applications. ACS Biomater. Sci. Eng. 11, 1253–1268 (2025).
Rodrigues, F. A. P. et al. Molecules in motion: unravelling the dynamics of vascularization control in tissue engineering. Macromol. Biosci. 24, 2400139 (2024).
Neishabouri, A., Soltani Khaboushan, A., Daghigh, F., Kajbafzadeh, A. -M. & Majidi Zolbin, M. Decellularization in tissue engineering and regenerative medicine: evaluation, modification, and application methods. Front. Bioeng. Biotechnol. 10, 805299 (2022).
Rathnam, C. et al. Hybrid SMART spheroids to enhance stem cell therapy for CNS injuries. Sci. Adv. 7, eabj2281 (2021).
Torabinavid, P., Khosropanah, M. H., Azimzadeh, A. & Kajbafzadeh, A. -M. Current strategies on kidney regeneration using tissue engineering approaches: a systematic review. BMC Nephrol. 26, 66 (2025).
Abbaszadeh, S. et al. Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: insights from islets and beyond. Adv. Drug Deliv. Rev. 200, 115050 (2023).
Ajima, K. et al. A porcine islet-encapsulation device that enables long-term discordant xenotransplantation in immunocompetent diabetic mice. Cell Rep. Methods 3, 100370 (2023).
Keymeulen, B. et al. Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes. Nat. Biotechnol. 42, 1507–1514 (2024).
Zhang, K. et al. Concepts and applications of digital twins in healthcare and medicine. Patterns 5, 101028 (2024).
Keyue, X. & Qiongfang, D. China’s first AI hospital town debuts: revolutionizing healthcare with artificial intelligence (Global Times, 2024).
Hein, D. et al. Prompts to table: specification and iterative refinement for clinical information extraction with large language models. Preprint at medRxiv https://doi.org/10.1101/2025.02.11.25322107 (2025).
Liu, X. et al. A generalist medical language model for disease diagnosis assistance. Nat. Med. 31, 932–942 (2025).
Tozuka, R. et al. Application of NotebookLM, a large language model with retrieval-augmented generation, for lung cancer staging. Jpn. J. Radiol. 43, 706–712 (2024).
Singh, R. et al. ChatGPT vs. Gemini: comparative accuracy and efficiency in lung-RADS score assignment from radiology reports. Clin. Imaging 121, 110455 (2025).
Villani, V., Nguyen, H. -H. T. & Shanmugarajah, K. Evaluating quality and readability of AI-generated information on living kidney donation. Transplant. Direct 11, e1740 (2024).
Demirbaş, K. C. et al. The potential of ChatGPT as a source of information for kidney transplant recipients and their caregivers. Pediatr. Transplant. 29, e70068 (2025).
Temsah, A. et al. DeepSeek in healthcare: revealing opportunities and steering challenges of a new open-source artificial intelligence frontier. Cureus 17, e79221 (2025).
Bedi, S. et al. Testing and evaluation of health care applications of large language models: a systematic review. JAMA 333, 319–328 (2025).
Miao, J., Thongprayoon, C., Craici, I. M. & Cheungpasitporn, W. How to improve ChatGPT performance for nephrologists: a technique guide. J. Nephrol. 37, 1397–1403 (2024).
Horgan, S., Vanuno, D., Sileri, P., Cicalese, L. & Benedetti, E. Robotic-assisted laparoscopic donor nephrectomy for kidney transplantation. Transplantation 73, 1474–1479 (2002).
Giulianotti, P. C. et al. Robot-assisted right lobe donor hepatectomy. Transpl. Int. 25, e5–e9 (2012).
Boggi, U. et al. Laparoscopic robot-assisted pancreas transplantation: first world experience. Transplantation 93, 201–206 (2012).
Emerson, D., Catarino, P., Rampolla, R., Chikwe, J. & Megna, D. Robotic-assisted lung transplantation: first in man. J. Heart Lung Transplant. 43, 158–161 (2024).
Lu, Y., Zhou, Y., Ju, R. & Chen, J. Human-animal chimeras for autologous organ transplantation: technological advances and future perspectives. Ann. Transl. Med. 7, 576 (2019).
Tan, T. et al. Chimeric contribution of human extended pluripotent stem cells to monkey embryos ex vivo. Cell 184, 3589 (2021).
Lebret, A. Allocating organs through algorithms and equitable access to transplantation—a European human rights law approach. J. Law Biosci. 10, lsad004 (2023).
US Food and Drug Administration. Current Good Manufacturing Practice regulations for drugs (21 CFR Parts 210 & 211) (2023).
US Food and Drug Administration. Expedited programs for regenerative medicine therapies for serious conditions—guidance for industry (2019).
US Food and Drug Administration. CBER standards recognition program for regenerative medicine therapies standard recognition summary (SRS) (2023).
European Commission. Regulation (EC) no. 1394/2007 of the European parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) no. 726/2004—EU requirements for ATMP authorization and hospital exemption (2007).
Zhang, J. et al. Standardisation is the key to the sustained, rapid and healthy development of stem cell-based therapy. Clin. Transl. Med. 14, e1646 (2024).
World Health Organization. WHO releases AI ethics and governance guidance for large multi-modal models (2024).
European Commission. Proposal for a Regulation on the European Health Data Space (2022).
US Food and Drug Administration. Artificial intelligence and machine learning in software as a medical device (2025).
Wang, W., He, W., Ruan, Y. & Geng, Q. First pig-to-human heart transplantation. Innovation 3, 100223 (2022).
Cooper, D. K. C. et al. Regulation of clinical xenotransplantation—time for a reappraisal. Transplantation 101, 1766–1769 (2017).
Hawthorne, W. J. et al. Third WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials, Changsha, Hunan, China December 12–14, 2018: ‘The 2018 Changsha Communique’ The 10-year anniversary of The International Consultation on Xenotransplantation. Xenotransplantation 26, e12513 (2019).
Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. US Public Health Service Guideline on infectious disease issues in xenotransplantation. MMWR Recomm. Rep. 50, 1–46 (2001).
US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans–guidance for industry (2016).
Hawthorne, W. J., Cowan, P. J., Buhler, L. & Wolf, E. International standards and guidelines for xenotransplantation. Nat. Biotechnol. 39, 1501–1502 (2021).
Fishman, J. A., Scobie, L. & Takeuchi, Y. Xenotransplantation‐associated infectious risk: a WHO consultation. Xenotransplantation 19, 72–81 (2012).
World Health Organization. First WHO global consultation on regulatory requirements for xenotransplantation clinical trials: Changsha, China, 19–21 November 2008. The Changsha Communiqué. Xenotransplantation 16, 61–63 (2009).
Harris, A. R., Walker, M. J. & Gilbert, F. Ethical and regulatory issues of stem cell-derived 3-dimensional organoid and tissue therapy for personalised regenerative medicine. BMC Med. 20, 499 (2022).
Witten, C. M., McFarland, R. D. & Simek, S. L. Concise review: the US food and drug administration and regenerative medicine. Stem Cells Transl. Med. 4, 1495–1499 (2015).
US Food and Drug Administration. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. FDA-2017-D-6146 (2020).